Comparison of Respiratory Syncytial Virus Versus Influenza-Associated Acute Respiratory Illness Hospitalizations Among Adults in North America
Infectious Diseases and Therapy · 03.11.2026
DOI: 10.1007/s40121-026-01468-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Infectious Diseases and Therapy, online erschienen am 03.11.2026. Verfasst von Negar Aliabadi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., New York, NY, 10001, USA. negar.aliabadi@pfizer.com. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Introduction
Respiratory syncytial virus (RSV) and influenza cause substantial acute respiratory illness (ARI) and may be difficult to distinguish clinically. We compared characteristics of adults hospitalized with ARI, diagnosed with RSV versus influenza, using standardized systematic testing.
Methods
The North American Multi-specimen prospective cohort study was conducted in the US and Canada during two respiratory seasons (2021–2023). Patients aged ≥ 40 years hospitalized with ARI/ARI-compatible symptoms, with symptom onset 7 days trended higher for RSV (64.4% vs. 55.8%, p = 0.1267). Disease severity was similar.
Conclusions
In a systematically tested cohort of adults with ARI, across US and Canadian sites, clinical characteristics and disease burden were largely similar for adults with influenza compared to those with RSV. These similarities highlight the need for multiplex viral testing and pathogen-specific surveillance strengthening to improve understanding of disease burden for these viruses that contribute significantly to morbidity and mortality across vulnerable populations. Additionally, with the recent licensure of older adult RSV vaccines, improved characterization of RSV-associated hospitalizations will facilitate vaccine impact evaluations and inform age-specific or risk-based vaccination strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pfizer Inc., New York, NY, 10001, USA. negar.aliabadi@pfizer.com.
- Epi Care Consulting LLC, Atlanta, GA, 30314, USA.
- Brown University, Providence, RI, 02912, USA.
- Pfizer Inc., Collegeville, PA, 19426, USA.
- Sinai Health System, Toronto, M1G1X5, Canada.
- Norton Infectious Disease Institute, Norton Healthcare, Louisville, KY, 40202, USA.
Förderung
- Pfizer
Zitieren
APA
Aliabadi, N., Ali, H., Liu, Q., McGeer, A., Ramirez, J., Uppal, S., Furmanek, S., Katz, K., Chandler, T. R., Mubareka, S., Vermeiren, C., Zhong, Z., Welch, V., Gonzalez, E., Hubler, R., Gessner, B. D., & Begier, E. (2026). Comparison of Respiratory Syncytial Virus Versus Influenza-Associated Acute Respiratory Illness Hospitalizations Among Adults in North America. Infectious Diseases and Therapy. https://doi.org/10.1007/s40121-026-01468-4
Vancouver
Aliabadi N, Ali H, Liu Q, McGeer A, Ramirez J, Uppal S, et al. Comparison of Respiratory Syncytial Virus Versus Influenza-Associated Acute Respiratory Illness Hospitalizations Among Adults in North America. Infectious Diseases and Therapy. 2026. doi:10.1007/s40121-026-01468-4
BibTeX
@article{Aliabadi2026,
author = {Aliabadi, Negar and Ali, Hammad and Liu, Qing and McGeer, Allison and Ramirez, Julio and Uppal, Sonal and Furmanek, Stephen and Katz, Kevin and Chandler, Thomas R and Mubareka, Samira and Vermeiren, Christie and Zhong, Zoe and Welch, Verna and Gonzalez, Elisa and Hubler, Robin and Gessner, Bradford D and Begier, Elizabeth},
title = {Comparison of Respiratory Syncytial Virus Versus Influenza-Associated Acute Respiratory Illness Hospitalizations Among Adults in North America},
journal = {Infectious Diseases and Therapy},
year = {2026},
doi = {10.1007/s40121-026-01468-4}
}
EUVIMED